We verify infection and define the syndrome before anything else
Stem cell therapy for Lyme disease in Istanbul, Turkey
Our Istanbul team confirms your diagnosis, protects recommended antibiotic care, and is honest about the limits of cell therapy for Lyme disease.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Evidence position
What is known, what is investigational, and what is not demonstrated
Infection confirmation before any cell discussion
We rely on exposure history, objective manifestations, and validated antibody testing rather than unvalidated panels.
We won't add risk to active infection
Recommended antibiotics depend on your specific presentation, and we make sure you get the right one.
No route clears Borrelia
Results vary between patients and stem cell therapy is not a guaranteed cure — persistent symptoms get supportive care and honest evaluation, not a promise of bacterial eradication by cells.
Clinical map
Start with the diagnosis, stage, and treatment context
The correct first question is whether Lyme disease is present and active, not which cell route to use.
Established care comes first
- Validated diagnosis: We use clinical criteria and recommended testing rather than non-validated panels.
- Manifestation-specific antibiotics: We choose drug, route, and duration according to your confirmed presentation and history.
- Persistent-symptom care: We review sleep, mood, pain, and other diagnoses that might explain ongoing symptoms.
- 01
Early localized or disseminated disease
Erythema migrans and certain neurologic or cardiac manifestations have defined diagnostic and antibiotic pathways.
- 02
Lyme arthritis or neuroborreliosis
Objective joint swelling or neurologic findings require specialist confirmation and manifestation-specific care.
- 03
Persistent symptoms after treatment
Fatigue, pain, or cognitive symptoms can be real and disabling, and we take them seriously while looking for the actual cause.
Direct answer
What the current evidence says
We don't offer stem cells or exosomes as a cure for Lyme disease, because no cell product eradicates Borrelia or resolves post-treatment symptoms. Our physicians first confirm whether active infection, persistent symptoms after treatment, or an alternate diagnosis best explains what you're experiencing, and make sure recommended antibiotics and complication care come first. Request your free medical evaluation for an honest, thorough review.
Evidence ledger
Read the actual study, including the result that did not change
Each row keeps product identity, route, endpoint, and limitation together so one trial cannot become a generic treatment claim.
01 AAN, ACR, and IDSA Lyme disease guideline
Open source- Product
- Recommended diagnostic and antimicrobial pathways
- Route
- Manifestation-specific antibiotic route
- Design
- Multispecialty evidence-based clinical practice guideline
- Finding
- The guideline defines evidence-based testing and treatment for objective Lyme manifestations.
- Limitation
- It does not establish stem-cell or exosome therapy for infection or persistent symptoms.
Product and route
A mechanism is not a clinical outcome
- 01
We won't add risk to active infection
An immunomodulatory product may add uncertainty and must never substitute for antimicrobial and complication management.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
- 02
No route clears Borrelia
We're clear that IV, intrathecal, or exosome delivery has not been shown to eradicate infection.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
Outcomes before travel
Decide what meaningful change would look like
A baseline and a time point matter more than an isolated testimonial. These measures should be chosen before any intervention.
- 01
Objective manifestation resolution
- 02
Joint swelling, neurologic, or cardiac findings
- 03
Function, fatigue, pain, sleep, and cognition
- 04
Antibiotic side effects and infection complications
- 05
Evidence for alternate diagnoses
Specialist review
What a complete Istanbul review needs
Our Istanbul team confirms your diagnosis, protects recommended antibiotic care, and is honest about the limits of cell therapy for Lyme disease.
Records and baseline
- Geographic exposure, tick bite, rash, and timeline
- Validated antibody results and original laboratory reports
- Antibiotics, dose, duration, adherence, and response
- Neurologic, cardiac, and rheumatologic records
- Alternate diagnoses and the exact proposed plan and rationale
Safety and planning checks
- Syncope, chest pain, meningitis signs, or a hot swollen joint always gets urgent local care first.
- We won't repeat prolonged antibiotics or add an experimental product without a clear diagnosis and risk review.
- Your Istanbul consultation explicitly states when the evidence does not support active Lyme disease.
Transparent planning
Build the medical plan before the package
A quote should follow record review, product disclosure, route rationale, and a written follow-up plan. This page does not invent a universal price.
- Syncope, chest pain, meningitis signs, or a hot swollen joint always gets urgent local care first.
- We won't repeat prolonged antibiotics or add an experimental product without a clear diagnosis and risk review.
- Your Istanbul consultation explicitly states when the evidence does not support active Lyme disease.
Questions the plan must answer
- 01
We won't add risk to active infection: An immunomodulatory product may add uncertainty and must never substitute for antimicrobial and complication management.
- 02
No route clears Borrelia: We're clear that IV, intrathecal, or exosome delivery has not been shown to eradicate infection.
Primary reading
Guidelines, trials, and regulatory context
FAQ
Questions patients ask before an Istanbul review
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.